CTOs on the Move


 
Octave Health is the nation`s first practice supporting all aspects of emotional well-being.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.findoctave.com
  • 286 Madison Ave 22nd Floor
    New York, NY USA 10017
  • Phone: 415.360.3833

Executives

Name Title Contact Details

Funding

Octave raised $11M on 10/22/2019
Octave raised $20M on 05/25/2021

Similar Companies

Blackline Marketing

Blackline Marketing specializes in helping clients in the hospitality, travel, restaurant, health care, business services, retail and food/beverage industries create integrated marketing solutions that increase revenues and maximize long-term customer engagement. Blackline Marketing helps clients in the areas of brand strategy, customer strategy, integrated marketing planning and people/process development. Clients include Northcott Hospitality/Houlihan`s restaurants, Caribou Coffee Company, HealthSource Solutions, ARC/Value Village Stores, Pebble Creek Golf Club and the MN Women`s Public Golf Association.

SonarMD

SonarMD provides care management for complex chronic conditions that use high-cost drugs. Through enhanced patient engagement, care coordination, and specialty pharmacy optimization, we improve the experience for both patients and clinical teams.

Lutheran Senior Life

Lutheran Senior Life is one of the leading companies in Healthcare, Pharmaceuticals, and Biotech industry. Lutheran Senior Life is based in Cranberry Twp, PA. You can find more information on Lutheran Senior Life at www.lutheranseniorlife.org

Pharmaka

Pharmaka is a Flemington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Xenon Pharmateuticals

Xenon Pharmaceuticals (NASDAQ:XENE) – a biopharmaceutical company with operations in Vancouver, BC, Canada and Boston, MA, U.S.A. – is committed to delivering innovative medicines to provide a brighter future for patients suffering from neurological disorders. At Xenon, we are advancing an exciting pipeline of neurology-focused therapies, with a particular emphasis on novel treatments for both adult and pediatric patients with epilepsy. XEN496 is currently being evaluated in the Phase 3 “EPIK” clinical trial in young patients with KCNQ2-DEE, a rare and severe form of childhood epilepsy. Late-stage development plans are also underway for our XEN1101 program, building upon the compelling data from the Phase 2b “X-TOLE” study in adult patients with focal epilepsy. We are also proud of the leading-edge science coming out of our discovery labs, with many early-stage research programs underway. In addition to Xenon`s proprietary programs, we have ongoing collaborations with our valued pharmaceutical partners. With a healthy balance sheet to support our growth plans, we continue to build a fully-integrated, premier neuroscience company with strong discovery, development, and commercial operations. Our employees are smart, passionate, dedicated, and driven by their incredibly important work to discover, develop, and deliver new medicines for patients in need. Building and maintaining a respectful, collaborative, inclusive, and productive culture is a priority for us. We are looking for great people who thrive in a fast-paced, dynamic work environment to join our team during this transformative time for Xenon.